Acceleron Pharma Inc (XLRN) : Hillhouse Capital Management Ltd. added new position in Acceleron Pharma Inc during the most recent quarter end. The investment management firm now holds 300,000 shares of Acceleron Pharma Inc which is valued at $12,054,000 , the company said in a statement filed on Nov 14, 2016 with the SEC.Acceleron Pharma Inc makes up approximately 0.27% of Hillhouse Capital Management Ltd.’s portfolio.
Other Hedge Funds, Including , Tudor Investment Corp Et Al reduced its stake in XLRN by selling 7,382 shares or 52.21% in the most recent quarter. The Hedge Fund company now holds 6,758 shares of XLRN which is valued at $271,536. Acceleron Pharma Inc makes up approx 0.01% of Tudor Investment Corp Et Al’s portfolio. Laurion Capital Management Lp added XLRN to its portfolio by purchasing 690,000 company shares during the most recent quarter which is valued at $25,102,200. Acceleron Pharma Inc makes up approx 0.86% of Laurion Capital Management Lp’s portfolio.Citadel Advisors boosted its stake in XLRN in the latest quarter, The investment management firm added 160,977 additional shares and now holds a total of 169,640 shares of Acceleron Pharma Inc which is valued at $6,171,503. Acceleron Pharma Inc makes up approx 0.02% of Citadel Advisors’s portfolio. Tocqueville Asset Management sold out all of its stake in XLRN during the most recent quarter. The investment firm sold 19,750 shares of XLRN which is valued $558,925.
Acceleron Pharma Inc closed down -0.19 points or -0.50% at $37.96 with 4,55,457 shares getting traded on Monday. Post opening the session at $37.74, the shares hit an intraday low of $36.44 and an intraday high of $38.16 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Acceleron Pharma Inc reported $-0.55 EPS for the quarter, missing the analyst consensus estimate by $ -0.01 based on the information available during the earnings call on Nov 3, 2016. Analyst had a consensus of $-0.54.Analysts expectations of $ 4.19.
Many Wall Street Analysts have commented on Acceleron Pharma Inc. Citigroup Initiated Acceleron Pharma Inc on Sep 29, 2016 to “Neutral”, Price Target of the shares are set at $40.
Acceleron Pharma Inc. is a biopharmaceutical company focused on the discovery development and commercialization of therapeutic candidates that are based on the mechanisms that the human body uses to regulate the growth and repair of its cells and tissues. The Company’s research focuses on key natural regulators of cellular growth and repair particularly the Transforming Growth Factor-Beta (TGF-b) protein superfamily. By combining its discovery and development know-how including its knowledge of the TGF-b superfamily and its internal protein engineering and manufacturing capabilities the Company has built a discovery and development platform that has generated therapeutic candidates with new mechanisms of action. The Company has four internally discovered therapeutic candidates that are in clinical trials.